Multiple myeloma is incurable, and patients can eventually become refractory to multiple classes of treatment
Anti-CD38 monoclonal antibodies
Patients with triple-class refractory multiple myeloma can have more progressive disease, poor prognosis, and few treatment options remaining.
Patients can continue to progress and require additional therapies.1,3,4
CD38, cluster of differentiation 38.
- Mikhael J. Treatment options for triple-class refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2020;20(1):1-7.
- Bruno AS, Willson JL, Opalinska JM, et al. Recent real-world treatment patterns and outcomes in US patients with relapsed/refractory multiple myeloma. Expert Rev Hematol. 2020;13(9):1017-1025.
- Sonneveld P, Broijl A. Treatment of relapsed and refractory multiple myeloma. Haematologica. 2016;101(4):396-406.
- Yong K, Delforge M, Driessen C, et al. Multiple myeloma: patient outcomes in real-world practice. Br J Haematol. 2016;175(2):252-264.
Discover a unique mechanism of action
Register to stay up-to-date with important information about TECVAYLI™Sign Up
Connect with a Janssen Oncology representativeTalk With Us
Access resources to help patients receive TECVAYLI™Explore Resources